drugset / Trial / NCT02722811

Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis

NCT02722811

RandomizedParallel-groupOpen-labelTreatment

Summary

Primary aim: evaluate efficacy of subcutaneous injection of etanercept for moderate and severe knee osteoarthritis. Second aim: investigate the potentiality of serum cytokines (TNF-α, Interleukin 1-α (IL1-α), IL1-β, matrix metalloproteinases1 (MMP1), MMP13) to predict the response of subcutaneous injection of etanercept for moderate and severe knee osteoarthritis.

Timeline

Start
2016-02
Primary completion
2017-07
Completion
2017-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications